

Crystal Structure of AGT: Insights for the Development of Therapeutic Agents

Chris Danpure
Department of Biology
University College London



“In human genetic disease, most point mutations in protein-encoding genes impair protein folding &/or oligomerization, producing aberrant conformations that result in protein **aggregation**, **accelerated degradation** and/or **incorrect trafficking**”

In PH1, there are mutations in AGT that result in:-

aggregation

accelerated degradation


abnormal trafficking

loss of catalytic activity

Challenge:-

to formulate (designer) therapeutic strategies that counter the effects of these mutations

AGT rapidly
homodimerizes into
a very stable dimer




Zhang et al., J. Mol. Biol.
331, 643-652 (2003)

Rate of AGT
dimerization

slightly
decreased

Zhang et al., J. Mol. Biol.
331, 643-652 (2003)




Lumb et al., J. Biol. Chem.
274, 20587-96 (1999)

Rate of AGT dimerization

greatly
decreased


Zhang et al., J. Mol. Biol.
331, 643-652 (2003)



Lumb et al., J. Biol. Chem.
274, 20587-96 (1999)


Pro11Leu
Pro10Leu

Removal of first 37 aa **abolishes dimerization**




Lumb et al., J. Biol. Chem.
274, 20587-96 (1999)

Zhang et al., J. Mol. Biol.
331, 643-652 (2003)



Rate of AGT
dimerization
greatly
decreased


Zhang et al., J. Mol. Biol.
331, 643-652 (2003)



Results in
peroxisome to
mitochondrion
mistargeting


Lieper et al., J. Cell Biol. 135, 939-951 (1996)

Normal & Mutant AGT cDNA Expressed in COS Cells (Laser-Scanning Confocal Immunofluorescence Microscopy)



Normal

AGT = Peroxisomal



Mutant

AGT = Mitochondrial
+ Peroxisomal


AGT = green
Mitochondria = red
Co-localization = yellow

Motley et al., J. Cell Biol. 131, 95-109 (1995)

AGT

**dimerization
abolished**



Zhang et al., J. Mol. Biol.
331, 643-652 (2003)



Danpure et al.,
Am. J. Hum. Genet.
53, 417-432 (1993)





**Results in
intraperoxisomal
aggregation**

PH1 patients expressing
Pro11Leu + Gly41Arg AGT
have amorphous
peroxisomal cores



Danpure et al.,
Am. J. Hum. Genet.
53, 417-432 (1993)



**Peroxisomal
cores are
made of
AGT**



Danpure et al.,
Am. J. Hum. Genet.
53, 417-432 (1993)

AGT
(10 nm)





Catalase
(20 nm)



a


Danpure et al.,
Am. J. Hum. Genet.
53, 417-432 (1993)

**Peroxisomal
cores
contain AGT
but not
four other
peroxisomal
proteins**



Danpure et al.,
Am. J. Hum. Genet.
53, 417-432 (1993)

Normal Pro11Leu+Gly41Arg heterozygotes
have both aggregated and soluble AGT



Danpure et al., *Am. J. Hum. Genet.* 53, 417-432 (1993)

Mutations that interfere with AGT folding
&/or dimerization result in:-

1) Peroxisome-to-mitochondrion mistargeting

(Pro11Leu + Gly170Arg)

- DIMERIZATION DELAYED


2) Intraperoxisomal aggregation

(Pro11Leu + Gly41Arg)

- DIMERIZATION ABOLISHED

Rate of AGT dimerization **slightly decreased**
& catalytic activity
diminished


Lumb & Danpure, J. Biol. Chem.
275, 36415-22 (2000)



Zhang et al., J. Mol. Biol.
331, 643-652 (2003)

Rate of AGT dimerization & catalytic activity significantly improved


Lumb & Danpure, J. Biol. Chem.
275, 36415-22 (2000)



Zhang et al., J. Mol. Biol.
331, 643-652 (2003)

Zhang et al., J. Mol. Biol. 331, 643-652 (2003)


Rate of AGT
dimerization
greatly
decreased



Results in
peroxisome to
mitochondrion
mistargeting

Mutant AGT

(Pro11Leu + Gly170Arg)




**AGT = Mitochondrial
+ Peroxisomal**

Lumb, Birdsey & Danpure.
Biochem. J. 374, 79-87 (2003).

Mutant AGT


(Pro11Leu + Gly170Arg)



AGT = Peroxisomal


AGT = green
Mitochondria = red
Co-localization = yellow

Pro11Leu + Gly170Arg



PEROX + MITO


Pro11Leu + Gly170Arg
+ GLYCEROL



PEROX


Lumb, Birdsey & Danpure. *Biochem. J.* 374, 79-87 (2003).

Pro11Leu + Gly170Arg



PEROX + MITO

Pro11Leu + Gly170Arg
+ GLYCEROL



PEROX

Lumb, Birdsey & Danpure. *Biochem. J.* 374, 79-87 (2003).

CONCLUSIONS

1) Several mutations in AGT interfere with its dimerization, leading to its aggregation, accelerated degradation &/or peroxisome-to-mitochondrion mistargeting.

2) Knowledge of AGT crystal structure provides insights into the mechanism of AGT dimerization & provides an explanation for how it is perturbed by several mutations.

CONCLUSIONS

3) Treatments that stabilise the AGT dimer or increase rate of AGT dimerization counteract the effects of at least some mutations.

4) Knowledge of AGT crystal structure & the identification of binding sites for chemical chaperones, such as glycerol, should enable design of pharmacological agents of high affinity and specificity that can stabilise the AGT dimer.

AGT mistargeting

J. Cell Biol. 108 (1989)

J. Cell. Biol. 111 (1990)

AGT aggregation

Am. J. Hum. Genet. 53 (1993)

AGT targeting/dimerization

J. Cell Biol. 131 (1995)

J. Cell Biol. 135 (1996)

J. Biol. Chem. 274 (1999)

Polymorphism-mutation

synergism

J. Biol. Chem. 275 (2000)

Normalisation of

AGT targeting

Biochem. J. 374 (2003).

AGT crystal structure

Acta Cryst. D57 (2001)

J. Mol. Biol. 331 (2003).

THE END